Management of Myositis-Related Interstitial Lung Disease
Management of Myositis-Related Interstitial Lung Disease
复制标题
DOI：
10.1016/j.chest.2016.04.007
复制
发表时间：
2016-11-01
期刊：
影响因子：
9.6
通讯作者：
Lee, Joyce S.
中科院分区：
文献类型：
--
作者：
Morisset, Julie;Johnson, Cheilonda;Lee, Joyce S.
间质性肺病（ILD）是特发性炎性肌病患者常见的肺部表现，也是导致发病率和死亡率的重要原因。肌炎相关ILD对临床医生提出了治疗挑战，因为没有可用的指南来帮助管理决策。本综述涵盖了肌炎相关ILD的药物和非药物管理的现有证据，强调缺乏指导治疗的随机对照数据。由于缺乏现有的指导方针，以告知治疗决策，我们提供了一个全面的总结，包括剂量，副作用，并建议监测常用的免疫抑制剂和建议的治疗算法的基础上，现有的文献。
Interstitial lung disease (ILD) is a frequent pulmonary manifestation and an important cause of morbidity and mortality in patients with idiopathic inflammatory myopathy. Myositis-related ILD presents a therapeutic challenge for clinicians, as there are no available guidelines to help with management decisions. This review covers the existing evidence on the pharmacologic and nonpharmacologic management of myositis-related ILD, highlighting the lack of randomized controlled data to guide treatment. Given the absence of existing guidelines to inform treatment decisions, we provide a comprehensive summary, including dosing, side effects, and suggested monitoring of the commonly used immunosuppressive agents and a proposed treatment algorithm based on the existing literature.